pharma · Squamous Cell Carcinoma of Head and Neck · Breast Cancer · TVRD
Tvardi Therapeutics
Tvardi Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Houston, USA
- Founded
- 2017
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 6
Tvardi Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Tvardi Therapeutics.
Tvardi Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
TTI-101
Tvardi Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial -
TTI-101
Tvardi Therapeutics
Hepatocellular Carcinoma
1 trial -
TTI-101
Tvardi Therapeutics
Idiopathic Pulmonary Fibrosis
1 trial -
Control Group
Tvardi Therapeutics
Squamous Cell Carcinoma of Head and Neck
1 trial -
TTI-101
Tvardi Therapeutics
Breast Cancer
2 trials -
TTI-101
Tvardi Therapeutics
Pancreatic Cancer
1 trial
Frequently asked questions
How many clinical projects does Tvardi Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.